I'm really pleased to share a new Board appointment for @4DMedicalXV - Brett Sandercock joins us from today as an independent Non-Executive Director. Brett brings more than 30 years of finance leadership in global healthcare technology. He spent 27 years at ResMed (NYSE:RMD, ASX:RMD), including 20 years as Chief Financial Officer from 2006 until his retirement in May this year.
Brett has lived the journey we are on. At ResMed he helped take an Australian respiratory technology company and build it into a global leader, through US market expansion, reimbursement, M&A and two decades of disciplined capital allocation. As we scale CT:VQ® across the US and Europe, and integrate our recent acquisitions, that experience is directly relevant to the decisions in front of us.
Few executives combine his commercial judgement with such a deep understanding of healthcare technology, and I look forward to working closely with him.
The full announcement is here: asx.api.cmfyapp.com/asx-research/1…
Brett has lived the journey we are on. At ResMed he helped take an Australian respiratory technology company and build it into a global leader, through US market expansion, reimbursement, M&A and two decades of disciplined capital allocation. As we scale CT:VQ® across the US and Europe, and integrate our recent acquisitions, that experience is directly relevant to the decisions in front of us.
Few executives combine his commercial judgement with such a deep understanding of healthcare technology, and I look forward to working closely with him.
The full announcement is here: asx.api.cmfyapp.com/asx-research/1…